相关实验视频

Updated: Jun 22, 2025

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

长时间的Prime-Boost间隔和增强的抗GD2抗体对碳水化合物癌症疫苗的反应

Irene Y Cheung¹, Audrey Mauguen², Shakeel Modak¹

¹Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

|June 27, 2024

概括

在神经母细胞瘤患者中,使用辅助β-葡萄糖的GD2/GD3癌症疫苗重复治疗显著提高了抗GD2IgG1抗体水平. 较高的抗体标位与改善的生存率和没有增加的副作用相关,这表明增强癌症免疫疗法的潜力.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
疫苗学疫苗学疫苗学

背景情况:

高风险神经母细胞瘤的治疗通常涉及免疫疗法,向像GD2.2这样的氏体抗原.
以前的研究表明,GD2/GD3癌症疫苗添加β-葡萄糖诱导抗GD2IgG1抗体,与改善无进展生存 (PFS) 和整体生存 (OS) 相关联.
了解在再接种疫苗时的抗体反应对于优化治疗策略至关重要.

研究的目的:

评估在患有复发性高风险神经母细胞瘤的患者中重新使用辅助β-葡萄糖的GD2/GD3癌症疫苗的免疫性和临床结果.
评估安全性,并将抗体标位与生存终点相关联.
调查影响疫苗反应的潜在遗传因素.

主要方法:

32名患有复发高风险神经母细胞瘤的患者接受了GD2/GD3癌症疫苗和β-葡萄糖辅助剂的再治疗.
在重新接种疫苗之前和之后测量了抗GD2IgG1抗体标位.
使用Kaplan-Meier方法分析了无进展生存率 (PFS) 和总生存率 (OS).
研究了抗体标位,德-1单核酸多态 (SNP) rs3901533和临床结果之间的关联.

主要成果:

与最初的注册相比,重新注册疫苗导致抗GD2 IgG1抗体标位的显著和快速增加 (4066 ± 813 ng/mL vs. 751 ± 270 ng/mL).
尽管最初的高峰值,但头随着反复的提升而急剧下降,并在第20周恢复到最初的水平.
在重新注册期间,估计的PFS为51%和OS为81%.
没有观察到增加的疼痛或神经病的副作用,与单克隆抗GD2抗体不同.
在IgG1标位和德-1受体SNP rs3901533 (p = 0.01) 之间发现了显著的关联.

结论:

用GD2/GD3癌症疫苗重新接种疫苗会在神经母细胞瘤患者中引起强烈但暂时的抗体反应.
该疫苗显示出良好的安全性,并与有希望的长期生存结果相关联.
优化主要提升间隔,并考虑宿主遗传因素,如dectin-1SNP,可能会提高类结合癌症疫苗的疗效.

关键词:

抗GD2 IgG1 标位抗GD2 IgG1 标位这是一种β-glucan.德克丁-1 SNP rs390153333 的使用情况甘地化物GD2/GD3碳水化合物疫苗高风险神经母细胞瘤

更多相关视频

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

相关概念视频

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccinations

Vaccinations

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.